Brokerages Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) Target Price at $22.56

Ocular Therapeutix, Inc. (NASDAQ:OCUL) has earned an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $24.00.

Several research firms have weighed in on OCUL. Chardan Capital reaffirmed a “buy” rating and set a $21.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, December 9th. Wall Street Zen lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Needham & Company LLC reissued a “buy” rating and set a $20.00 target price on shares of Ocular Therapeutix in a research note on Monday, December 8th. HC Wainwright increased their price objective on Ocular Therapeutix from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $30.00 target price on shares of Ocular Therapeutix in a research note on Thursday.

Ocular Therapeutix Stock Up 4.2%

OCUL stock opened at $8.91 on Tuesday. The company’s 50 day simple moving average is $11.88 and its 200-day simple moving average is $11.95. Ocular Therapeutix has a 52-week low of $5.78 and a 52-week high of $16.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 7.85 and a quick ratio of 7.78. The firm has a market capitalization of $1.90 billion, a P/E ratio of -6.19 and a beta of 0.90.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.05. The company had revenue of $13.25 million for the quarter. Ocular Therapeutix had a negative net margin of 447.57% and a negative return on equity of 86.33%. Ocular Therapeutix’s revenue for the quarter was down 22.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.29) earnings per share. As a group, equities research analysts anticipate that Ocular Therapeutix will post -0.98 EPS for the current year.

Insiders Place Their Bets

In other Ocular Therapeutix news, COO Donald Notman sold 6,035 shares of Ocular Therapeutix stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $8.54, for a total value of $51,538.90. Following the completion of the sale, the chief operating officer directly owned 377,802 shares in the company, valued at $3,226,429.08. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.30% of the company’s stock.

Hedge Funds Weigh In On Ocular Therapeutix

Hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC lifted its position in shares of Ocular Therapeutix by 62.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,392 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Ocular Therapeutix by 17.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 893 shares during the last quarter. KBC Group NV bought a new stake in Ocular Therapeutix during the fourth quarter worth approximately $78,000. Quarry LP bought a new position in shares of Ocular Therapeutix in the third quarter valued at approximately $80,000. Finally, Trust Co. of Vermont lifted its stake in shares of Ocular Therapeutix by 24.3% in the fourth quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,750 shares during the last quarter. 59.21% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Ocular Therapeutix

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Q4 EPS beat — Ocular reported GAAP EPS of ($0.29) vs. consensus ($0.34), a small beat that can be read as a modest near‑term positive on profitability trajectory and helped limit downside. Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
• Positive Sentiment: Analyst support remains – multiple firms continue buy/outperform ratings and the consensus price target sits well above current levels, providing potential upside if clinical/readout news is favorable. Ocular Therapeutix Stock Page
• Neutral Sentiment: Company released its full Q4 and FY2025 financial results and business highlights; the report gives more detail on revenue drivers, pipeline timelines and cash position that investors will parse ahead of the pivotal readout. Ocular Therapeutix: Q4 Earnings Snapshot
• Negative Sentiment: Revenue miss and year‑over‑year decline — Q4 revenue of $13.25M was down ~22% YoY and missed some estimates, a clear negative for near‑term growth expectations. Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates
• Negative Sentiment: Rival publicity ahead of readout — Eyepoint Pharmaceuticals publicly challenged Ocular on the eve of a pivotal trial readout, raising competitive and perception risk that can pressure the stock ahead of binary clinical news. A rival goes after Ocular Therapeutix on eve of pivotal readout on eye treatment
• Negative Sentiment: Insider selling — COO Donald Notman sold shares in early February (multiple transactions), which can be interpreted negatively by some investors even if part of routine diversification. Donald Notman Sells 5,455 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock
• Negative Sentiment: Unusual bearish options activity — traders purchased an elevated number of put options (large spike vs. average), signaling short-term bearish positioning ahead of the readout and amplifying volatility risk.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.